author-photo

David Starks

Case Western Reserve University

28

Papers

362

Citations

Citation Trend

Filter By

Papers (28) Sort By

JournalConferenceOthers

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1597: The landscape of PD1-PD-L1 axis in the context of immune cells: Tumors versus stromal compartments

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 1427: Co-alteration of the nucleosome remodeler, ARID1A with the PI3K-pathway genes: A signaling opportunity in ovarian cancers

2020 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancer

2019 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 4579: A comparative immune-landscape within tumor-microenvironment: Pattern of distribution of immune cells in tumor versus tumor-adjacent normal tissues

2019 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 644: Validation of PD-L1 staining by IHC in solid tumors: A journey from xenograft model to ex vivo culture of clinical samples

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3451: Testing signaling algorithm in platinum-resistant ovarian carcinomas: A simultaneous inhibition of RAS-RAF and cell-cycle pathways signals by trametinib with paclitaxel or ribociclib/abemaciclib

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B092: Molecular aberrations of the PI3K-AKT-mTORC1/C2 pathway in ovarian cancers: a strategy for targeted therapy

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Abstract B093: Signaling algorithm based on RAS-RAF and cell-cycle pathways’ alterations in precision medicine: rational combination of drugs in ovarian carcinoma

2018 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号